张雪梅

1995 - 2000，复旦大学，药理学，博士

1990 - 1995，上海医科大学，药理学，学士

2024 – 至今 华东师范大学，药学院，教授

2014 – 2024 复旦大学，药学院，教授

2005 – 2014 复旦大学，药学院，副研究员

2000 – 2005 约翰霍普金斯大学博士后

张雪梅博士，现任华东师范大学药学院副院长，博士生导师。本科和博士毕业于上海医科大学和复旦大学药学院，约翰霍普金斯大学博士后。研究方向为代谢药理学，主要基于膜蛋白对代谢物的感知，应答和调控信号机制开展药物靶点发现和相应的新药开发研究。主持多项国家自然科学基金等二十余项国家和省部级科研项目。以通讯作者在Kidney Intl, Autophagy, J of cachexia sarcopenia muscle, J control release等高水平杂志发表文章七十余篇，他引1800余次。参与获得1类新药临床试验批件1项。担任多家国际学刊编委，主参编“药理学“等规划教材和专著十五部。现任教育部高等学校药学类专业教指委委员和(大)药学专业分委会副主任委员、全国药学专业认证工作委员会委员、中国药理学会理事和肾脏药理专委会常务委员、上海市药学会常务理事和老年药学专委会主任委员、上海市药理学会常务理事和教学专委会主任委员、人民卫生出版社全国高等学校药学类专业第六届教材评审委员会委员等职。获得第一届全国药学专业学位研究生教育教学成果奖一等奖（第一完成人），2022年上海市优秀教学成果奖一等奖（第一完成人）和2023年东方英才计划教师项目。曾获上海市三八红旗手和浦江人才计划。

教育部高等学校药学类专业教学指导委员会委员和(大)药学专业分委会副主任委员

教育部高等教育教学评估中心药学类专业认证工作委员会委员

中国药理学会理事及肾脏药理专业委员会常务委员

上海市药学会常务理事及老年药学专业委员会主任委员

上海市药理学会理事及教学专业委员会主任委员

人民卫生出版社全国高等学校药学类专业第六届教材评审委员会委员

1、代谢药理学

2、心血管药理学

3、体内外药理活性评价和新药发现

近五年代表性文章

1. WU T, WANG M, NING F, ZHOU S, HU X, XIN H, REILLY S, ZHANG X. Emerging role for branched-chain amino acids metabolism in fibrosis [J]. Pharmacol Res, 2023, 187:106604.(TOP 1区，IF=9.3)

2. ZHOU S, LV P, LI M, CHEN Z, XIN H, REILLY S, ZHANG X. SARS-CoV-2 E protein: Pathogenesis and potential therapeutic development [J]. Biomed Pharmacother, 2023, 159:114242.(TOP 1区，IF=7.5，highly cited paper)

3. XIA C, WANG Y, JIANG T, HU Y, CHEN Y, MA X,ZHANG X, GAO Y. Slo1 deficiency impaired skeletal muscle regeneration and slow-twitch fibre formation [J]. J Cachexia Sarcopenia Muscle, 2023, 14(4): 1737-52. (TOP 1区，IF=12.0)

4. Ning F, Du L, Li J, Wu T, Zhou J, Chen Z, Hu X, Zhang Y, Luan X, Xin H, Yuan C,Zhang X. The deubiquitinase USP5 promotes cholangiocarcinoma progression by stabilizing YBX1. Life Sci, 2024 29:122674 ( 2区，IF=6.1)

5. JIANG L, LI J, REILLY S, XIN H, GUO N,ZHANG X. Role of organellar Ca2+-activated K+ channels in disease development [J]. Life Sci, 2023, 316: 121433. ( 2区，IF=6.1)

6. ZHOU S, YU Z, CHEN Z, NING F, HU X, WU T, LI M, XIN H, REILLY S,ZHANG X. Olmesartan alleviates SARS-CoV-2 envelope protein induced renal fibrosis by regulating HMGB1 release and autophagic degradation of TGF-beta1 [J]. Front Pharmacol, 2023, 14: 1187818.( 2区，IF=5.6)

7. WANG Y, WANG M, REN D , NING F, TAO J, XIE W, EATON D, JIANG G, FARRIS A, XIN H, CAI H,ZHANG X. A Novel Role of BK Channel Activity in Preventing Development of Renal Fibrosis [J]. Kidney Int, 2022, 101(5):945-962.(TOP 1区，IF=19.6)

8. WANG M, ZENG F, NING F, WANG Y, ZHOU S, HE J, LI C, WANG C, SUN X, ZHANG D, XIAO J, HU P, REILLY S, XIN H, XU X, ZHANG X. Ceria nanoparticles ameliorates renal fibrosis by modulating the balance between oxidative phosphorylation and aerobic glycolysis [J]. Journal of Nanobiotechnology, 2022, 20(1):3.(TOP 1区，IF=10.2)

9. NING F L, TAO J, LI D D, TIAN L L, WANG M L, REILLY S, LIU C, CAI H, XIN H,ZHANG X M. Activating BK channels ameliorates vascular smooth muscle calcification through Akt signaling [J]. Acta Pharmacol Sin, 2022, 43(3): 624-33.(TOP 1区，IF=8.2)

10. HUANG Y, WANG B, HASSOUNAH F, PRICE SR, KLEIN J, MOHAMED TMA, WANG Y, PARK J, CAI H, ZHANG X, WANG XH. The impact of senescence on muscle wasting in chronic kidney disease[J] . J Cachexia Sarcopenia Muscle, 2022, 14(1):126-141.(TOP 1区，IF=12.0)

11. HUANG N, SUN X L, LI P, LIU X,ZHANG X M, CHEN Q, XIN H. TRIM family contribute to tumorigenesis, cancer development, and drug resistance [J]. Exp Hematol Oncol, 2022, 11(1):75.(TOP 1区，IF=10.9)

12. HE J, WANG M, YANG L, XIN H, BIAN F, JIANG G,ZHANG X. Astragaloside IV Alleviates Intestinal Barrier Dysfunction via the AKT-GSK3beta-beta-Catenin Pathway in Peritoneal Dialysis [J]. Front Pharmacol, 2022, 13: 873150.( 2区，IF=5.6)

13. CUI X, JIA H, XIN H, ZHANG L, CHEN S, XIA S, LI X, XU W, CHEN X, FENG Y, WEI X, YU H, WANG Y, ZHAN Y, ZHU X,ZHANG X. A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities [J]. Front Immunol, 2021, 12: 778978.(TOP 1区，IF=7.3)

14. JIANG L, YANG Q, GAO J, YANG J, HE J, XIN H, ZHANG X. BK Channel Deficiency in Osteoblasts Reduces Bone Formation via the Wnt/beta-Catenin Pathway [J]. Mol Cells, 2021, 44(8): 557-68. ( 2区，IF=3.8)

15. NING F L, XIN H, LIU J Q, LV C, XU X, WANG M L, WANG Y H, ZHANG W D,ZHANG XM. Structure and function of USP5: Insight into physiological and pathophysiological roles [J]. Pharmacological Research, 2020, 157:104557.(TOP 1区，IF=9.3)

16. HAN B, XIE W, ZHANG Y, ZHOU S, YANG J, WANG R, SUN Y, WANG X, XU J, CHEN D, WANG Y, LU J, NING F, SHEN F, LIU M, CAI H, XIN H, LU W, ZHANG X. The influx/efflux mechanisms of d-peptide ligand of nAChRs across the blood-brain barrier and its therapeutic value in treating glioma [J]. J Control Release, 2020, 327: 384-96.(TOP 1区，IF=10.8)

17. WANG L, HOU J, WANG J, ZHU Z, ZHANG W,ZHANG X, SHEN H, WANG X. Regulatory roles of HSPA6 in Actinidia chinensis Planch. root extract (acRoots)-inhibited lung cancer proliferation [J]. Clin Transl Med, 2020, 10(2): e46.(TOP 1区，IF=10.6)

18. WANG Y, TAO J, WANG M, YANG L, NING F, XIN H, XU X, CAI H, ZHANG W, YU K,ZHANG X. Mechanism of Regulation of Big-Conductance Ca(2+)-Activated K(+) Channels by mTOR Complex 2 in Podocytes [J]. Front Physiol, 2019, 10(167):1-13.( 2区，IF=4.0)

19. WANG Y, GUO Q, HEI H, TAO J, ZHOU Y, DONG J, XIN H, CAI H, GAO J, YU K, REILLY S, YIN P,ZHANG X. BK ablation attenuates osteoblast bone formation via integrin pathway [J]. Cell Death Dis, 2019, 10(10): 738.(TOP 1区，IF=9.0)

20. WANG Q, WU Z L, YUAN X, DONG H Y, XU X, XIN H, WANG Y H, ZHANG J B, CHEN L, LI H L,ZHANG XM, ZHANG WD. Bilobetin induces kidney injury by influencing cGMP-mediated AQP-2 trafficking and podocyte cell cycle arrest [J]. Phytomedicine, 2019, 64: 153073. (TOP 1区，IF=7.9)